TNF and inflammatory bowel disease: Indeed, 2 studies showed that only 19% to 36% of infliximab-treated children with VEOIBD were still on treatment at 12 months of therapy; moreover, the response rate at 12 months was 10% to 11% in patients with CD, 7% to 25% in patients with UC, and 0% in patients with IBD-U.6,14 Only recently, a North American study reported higher rates of anti-TNF persistence, likely due to differences in standard anti-TNF dosing or concomitant use of immunomodulators.15